Based on the Novartis AG ADR stock forecast from 2 analysts, the average analyst target price for Novartis AG ADR is USD 114.00 over the next 12 months. Novartis AG ADR’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Novartis AG ADR is Bullish , which is based on 7 positive signals and 3 negative signals. At the last closing, Novartis AG ADR’s stock price was USD 95.12. Novartis AG ADR’s stock price has changed by +0.75% over the past week, -1.15% over the past month and -5.16% over the last year.
No recent analyst target price found for Novartis AG ADR
No recent average analyst rating found for Novartis AG ADR
Company Overview Novartis AG ADR
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. It offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Read Less
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. It offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience...Read More
Frequently Asked Questions About Novartis AG ADR (NVS) Stock
Based on ratings from 2 analysts Novartis AG ADR's stock is Hold . Stock Target Advisor's fundamental analysis is Bullish . The stock has buy, sell and 2 hold ratings.
NVS stock's dividend yield is 3.94%.
Our analysis grades NVS stock's dividend yield at D+. This means that NVS stock's dividend yield is above 67% of the stocks in the Drug Manufacturers - General sector in the NYE exchange.
Based on this NVS may be a average dividend stock for its sector.
Based on targets from 2 analysts, the average taret price for NVS is USD 114.00 over the next 12 months. The maximum analyst target price is USD 114 while the minimum anlayst target price is USD 114.
NVS stock's Price/Earning ratio is 23.36.
Our analysis grades NVS stock's Price / Earning ratio at D+. This means that NVS stock's Price/Earning ratio is above 32.99999999999999% of the stocks in the Drug Manufacturers - General sector in the NYE exchange.
Based on this NVS may be fairly valued for its sector
The last closing price of NVS's stock was USD 95.12.
The most recent market capitalization for NVS is USD 195.80B.
Based on targets from 2 analysts, the average taret price for NVS is projected at USD 114.00 over the next 12 months.
This means that NVS's stock price may go up by +19.85% over the next 12 months.
Following are ETFs with the highest allocation to Novartis AG ADR's stock :
As per our most recent records Novartis AG ADR has 76,057 Employees.
Novartis AG ADR's registered address is Lichtstrasse 35, Basel, Switzerland, 4056.
You can get more information about it from Novartis AG ADR's website at https://www.novartis.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior total returns
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Superior Dividend Growth
This stock has shown top quartile dividend growth in the previous 5 years compared to its sector
What not to like
Poor capital utilization
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
Poor return on equity
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for NVS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
